On March 1, 2024, Crinetics Pharmaceuticals, Inc closed the transaction.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
51.34 USD | +1.69% | +4.13% | +44.63% |
10/05 | Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing | MT |
09/05 | Crinetics Pharmaceuticals Q1 Net Loss Widens | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.63% | 398.16Cr | |
+33.15% | 4.95TCr | |
+2.02% | 4.26TCr | |
+49.11% | 4.25TCr | |
-4.22% | 2.91TCr | |
+12.07% | 2.66TCr | |
-22.58% | 1.86TCr | |
+8.32% | 1.32TCr | |
+30.32% | 1.25TCr | |
+24.00% | 1.21TCr |
- Stock Market
- Equities
- CRNX Stock
- News Crinetics Pharmaceuticals, Inc.
- Crinetics Pharmaceuticals, Inc. announced that it has received $350.000028 million in funding from a group of investors